Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of olmesartan medoxomil + amlodipine + hydrochlorothiazide versus olmesartan medoxomil + hydrochlorothiazide in primary hypertension
CTR20241045Phase 3Completed
- Sponsor
- Shanghai Tenry Pharmaceutical Co., Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olmesartan, amlodipine, hydrochlorothiazide in essential hypertension, sponsored by Shanghai Tenry Pharmaceutical Co., Ltd.. Started Apr 2024; status: completed.
02
Drugs
olmesartanamlodipinehydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20241045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241045.